



1FW

Docket No.: 066821-0058

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Reed, John C., et al.
Appl. No. : 10/748,128
Filed : December 24, 2003
Title : METHODS AND COMPOSITIONS
FOR DEREPRESSION OF IAP-
INHIBITED CAPASE

Customer No.: 41552
Confirmation No.: 1734
CERTIFICATE OF MAILING (37 CFR. § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail as First Class Mail under 37 CFR 1.8(a) in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Mar 30 2005

Sarah Nunez

Grp./A.U. : 1646
Examiner: : To Be Assigned

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached form PTO-1449. Enclosed are five (5) newly cited references. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

Each English language reference was cited in a corresponding foreign application search report or office action and its relevance discussed therein.


10/748,128

The references marked with asterisks (**) were cited by or submitted to the U.S. Patent and Trademark Office in parent application Serial No. 10/302,811, filed November 21, 2002, which is relied upon for an earlier filing date under 35 USC 120. Thus, copies of these references are not attached. 37 CFR 1.98(d).

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 502624 and please credit any excess fees to such deposit account.


Respectfully submitted,

McDERMOTT WILL & EMERY LLP


Matthew V. Grumbling
Registration No. 44,427

4370 La Jolla Village Drive, Suite 700
San Diego, CA 92122
Phone: 858.535.9001 MVG:cej
Facsimile: 858.597.1585
Date: March 30, 2005

**Please recognize our Customer No. 41552
as our correspondence address.**

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	ATTY. DOCKET NO. 066821-0058		SERIAL NO. 10/748,128
	APPLICANT Reed et al.		
(SUBSTITUTED PTO-1449)	FILING DATE December 24, 2003		GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	**1	US 4,631,211	12-23-1986	Houghten	
	**2	US 5,556,762	09-17-1996	Pinilla et al.	
	3	US 5,766,848	06-16-1998	Borden et al.	
	4	US 6,159,709	12-12-2000	Korneluk et al.	
	**5	US 6,228,603 B1	05-08-2001	Reed et al.	
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation	
	**6	WO 92/09300	06-11-92	Iterex et al.		Yes	No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	**7	AMBROSINI et al., "A novel anti-apoptosis gene, <i>survivin</i> , expressed in cancer and lymphoma," <u>Nature Med.</u> 3:917-921 (1997).	
	8	BERTIN et al., "Apoptotic suppression by baculovirus P35 involves cleavage by and inhibition of a virus-induced CED-3/ICE-like protease," <u>J. Virol.</u> 70:6251-6259 (1996).	
	**9	BIRNBAUM et al., "An Apoptosis-Inhibiting Gene from a Nuclear Polyhedrosis Virus Encoding a Polypeptide with Cys/His Sequence Motifs," <u>J. Virol.</u> 68:2521-2528 (1994).	
	**10	BOLDIN et al., "Involvement of Mach, a Novel Mort1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death," <u>Cell</u> 85:803-815 (1996).	
	11	BUMP et al., "Inhibition of ICE family proteases by baculovirus antiapoptotic protein," <u>Science</u> 269:1885-1888(1995).	
	**12	CASCIOLA-ROSEN et al., "Apoptin/CPP32 Cleaves Proteins That Are Essential for Cellular Repair: a Fundamental Principle of Apoptotic Death," <u>J. Exp. Med.</u> 183:1957-1964 (1996).	
	**13	CHAI et al., "Structural and biochemical basis of apoptotic activation by Smac/DIABLO," <u>Nature</u> 406:855-862 (2000).	
	**14	CHEN et al., "A Human IAP-Family Gene, <i>Apollon</i> , Expressed in Human Brain Cancer Cells," <u>Biochem. Biophys. Res. Commun.</u> 264:847-854 (1999).	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** Previously cited in parent application 10/302,811

US Patents are not included.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	ATTY. DOCKET NO. 066821-0058	SERIAL NO. 10/748,128
	APPLICANT Reed et al.	
(SUBSTITUTED PTO-1449)	FILING DATE December 24, 2003	GROUP 1646

**15	DEVERAUX et al., "IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases," <u>EMBO J.</u> 17:2215-2223 (1998).	
16	DEVERAUX et al., "X-linked IAP is a direct inhibitor of cell-death proteases," <u>Nature</u> 388:300-304 (1997).	
**17	DEVERAUX and Reed, "IAP family proteins—suppressors of apoptosis," <u>Genes and Development</u> 13:239-252 (1999).	
**18	DOOLEY et al., "An All D-Amino Acid Opioid Peptide with Central Analgesic Activity from a Combinatorial Library," <u>Science</u> 266:2019-2022 (1994).	
**19	DU et al., "Smac, a Mitochondrial Protein That Promotes Cytochrome c-Dependent Caspase Activation by Eliminating IAP Inhibition," <u>Cell</u> 102:33-42 (2000).	
20	HAWKINS, et al. "Inhibition of Interleukin 1 Beta-converting enzyme-mediated apoptosis of mammalian cells by baculovirus IAP," <u>Proc. Nat'l Acad. Sci. (USA)</u> 93:13786-13790 (1996).	
**21	HOUGHTEN et al., "Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery," <u>Nature</u> 354:84-86 (1991).	
**22	KASOF AND GOMES, "Livin, a Novel Inhibitor of Apoptosis Protein Family Member," <u>J. Biol. Chem.</u> 276:3238-3246 (2001).	
**23	KHARBANDA et al., "Role for Bcl-x _L as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis," <u>Proc. Natl. Acad. Sci. USA</u> 94:6939-6942 (1997).	
**24	KLUCK et al., "The Release of Cytochrome c from Mitochondria: a Primary Site for Bcl-2 Regulation of Apoptosis," <u>Science</u> 275:1132-1136 (1997).	
**25	LI et al., "Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade," <u>Cell</u> 91:479-489 (1997).	
**26	LISTON et al., "Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes," <u>Nature</u> 379:349-353 (1996).	
**27	LIU et al., "Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c," <u>Cell</u> 86:147-157 (1996).	
**28	LIU et al., "DFF, a Heterodimeric Protein That Functions Downstream of Caspase-3 to Trigger DNA Fragmentation During Apoptosis," <u>Cell</u> 89:175-184 (1997).	
**29	LIU et al., "Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain," <u>Nature</u> 408:1004-1008 (2000).	
**30	MARTIN AND GREEN, "Protease Activation During Apoptosis: Death by a Thousand Cuts?," <u>Cell</u> 82:349-352 (1995).	
**31	MUZIO et al., "FLICE, a Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex," <u>Cell</u> 85:817-827 (1996).	
**32	REED AND TOMASELLI, "Drug discovery opportunities from apoptosis research," <u>Cur. Opin. Biotech.</u> 11:586-592 (2000).	
**33	REED, "Apoptosis-regulating proteins as targets for drug discovery," <u>Trends Mol. Med.</u> 7:314-319 (2001).	
**34	RIEDL et al., "Structural Basis for the Inhibition of Caspase-3 by XIAP," <u>Cell</u> 104:791-800 (2001).	
**35	ROTHER et al., "The TNFR2-TRAF Signaling Complex Contains Two Novel Proteins Related to Baculoviral Inhibitor of Apoptosis Proteins," <u>Cell</u> 83:1243-1252 (1995).	
**36	ROY et al., "The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases," <u>EMBO J.</u> 16:6914-6925 (1997).	
**37	SUN et al., "NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP," <u>Nature</u> 401:818-822 (1999).	
**38	SRINIVASULA et al., "Molecular Determinants of the Caspase-promoting Activity of Smac/DIABLO and its Role in the Death Receptor Pathway," <u>J. Bio. Chem.</u> 275:36152-36157 (2000).	
**39	SRINIVASULA et al., "A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis," <u>Nature</u> 410:112-116 (2001).	
**40	TAKAHASHI et al., "Cleavage of lamin A by Mch2γ but not CPP32: Multiple interleukin 1γ-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis," <u>Proc. Natl. Acad. Sci. USA</u> 93:8395-8400 (1996).	
**41	TAKAHASHI et al., "A Single BIR Domain of XIAP Sufficient for Inhibiting Caspases," <u>J. Biol. Chem.</u> 273:7787-7790 (1998).	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** Previously cited in parent application 10/302,811

US Patents are not included.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	ATTY. DOCKET NO. 066821-0058	SERIAL NO. 10/748,128
	APPLICANT Reed et al.	
(SUBSTITUTED PTO-1449)	FILING DATE December 24, 2003	GROUP 1646

	**42	UBEDA AND HABENER, "The Large Subunit of the DNA Replication Complex C (DSEB/RF-C140) Cleaved and Inactivated by Caspase-3 (CPP32/YAMA) During Fas-induced Apoptosis," <u>J. Biol. Chem.</u> 272:19562-19568 (1997).	
	**43	VERHAGEN et al., "Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins," <u>Cell</u> 102:43-53 (2000).	
	44	VILLA et al. "Caspases and caspase inhibitors," <u>TIBS</u> . 22(10):388-393 (1997).	
	**45	VUCIC et al., "ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas," <u>Cur. Biol.</u> 10:1359-1366 (2000).	
	**46	WANG et al., "Cleavage of sterol regulatory element binding proteins (SREBPs) by CPP32 during apoptosis," <u>EMBO J.</u> 15:1012-1020 (1996).	
	**47	WU et al., "Structural basis of IAP recognition by Smac/DIABLO," <u>Nature</u> 408:1008-1012 (2000).	
	**48	YANG et al., "Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked," <u>Science</u> 275:1129-1132 (1997).	
	**49	ZHOU et al., "Target Protease Specificity of the Viral Serpin Cma. ANALYSIS OF FIVE CASPASES," <u>J. Biol. Chem.</u> 272:7797-7800 (1997).	
	**50	ZHOU et al., "IL-10 Inhibits Apoptosis of Promyeloid Cells by Activating Insulin Receptor Substrate-2 and Phosphatidylinositol 3'- Kinase," <u>J. Immunol.</u> 167:4436-4442 (2001).	
	**51	ZOU et al., "Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c-Dependent Activation of Caspase-3," <u>Cell</u> 90:405-413 (1997).	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** Previously cited in parent application 10/302,811
US Patents are not included.